HUMA — Humacyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1818382 ·
Last close
$1.11
Market Cap
$246.44M
52W High
$1.31
52W Low
$0.55
ADV30
5,962,033
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 495,000 | -1,543,000 | -28,935,000 | -17,619,000 | 110,557,000 | 48,539,000 | 98,933,000 |
| Dec 2025 | 467,000 | -8,615,000 | -30,836,000 | -24,804,000 | 116,366,000 | 50,497,000 | 113,257,000 |
| Sep 2025 | 753,000 | 493,000 | -24,390,000 | -17,510,000 | 91,509,000 | 19,488,000 | 96,260,000 |
| Jun 2025 | 301,000 | 88,000 | -29,727,000 | -37,658,000 | 138,795,000 | 38,032,000 | 134,743,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-105,042,000
Investing CF
$-884,000
Financing CF
$61,486,000
CapEx
$-884,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-726,848,000
Inventory
$13,589,000
Receivables
$441,000
ST Investments
—
EBIT TTM
$-29,583,000
Pretax Income TTM
$-40,833,000
Interest Exp TTM
$11,250,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,016,000
EBITDA
$-105,185,000
Free Cash Flow
$-64,806,624
Enterprise Value
$264,403,216
Total Cash
$48,539,000
Total Debt
$66,501,000
Shares Out
222,019,108
Trailing EPS
$-0.64
Book Value
$0.02
ROE
-409.5%
ROA
-51.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,038,000 | -108,137,000 | -40,833,000 | 116,366,000 | 113,257,000 | — | -105,042,000 |
| Dec 2024 | 0 | -114,398,000 | -148,701,000 | 137,872,000 | 190,541,000 | — | -98,122,000 |
| Dec 2023 | 0 | -100,047,000 | -110,776,000 | 128,223,000 | 114,677,000 | — | -73,305,000 |
| Dec 2022 | 0 | -84,578,000 | -11,965,000 | 204,302,000 | 87,374,000 | — | -71,129,000 |
TTM Snapshot
Revenues TTM
$2,738,000
NetIncome TTM
$-130,394,000
OpCashFlow TTM
$0
Assets (Latest)
$137,872,000
Forward EPS
$-0.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALEC | Alector, Inc. | $243.15M | $2.19 | — |
| LENZ | LENZ Therapeutics, Inc. | $243.00M | $7.75 | — |
| FATE | FATE THERAPEUTICS INC | $250.60M | $2.15 | — |
| CGEN | COMPUGEN LTD | $250.65M | $2.65 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $251.14M | $2.71 | — |
News headlines (Yahoo Finance, 1h cache)
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
2026-05-26 12:00 · Yahoo
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
2026-05-20 12:00 · Yahoo
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
2026-05-19 11:08 · Yahoo
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ...
2026-05-13 23:02 · Yahoo
Humacyte (HUMA) Q1 2026 Earnings Transcript
2026-05-13 18:53 · Yahoo
Humacyte Q1 Earnings Call Highlights
2026-05-13 14:07 · Yahoo
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
2026-05-13 13:29 · Yahoo
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-13 12:35 · Yahoo
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-13 11:00 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.